Targetable alterations in invasive pleomorphic lobular carcinoma of the breast
Open Access
- 13 January 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 23 (1) , 1-8
Abstract
Background: Invasive pleomorphic lobular carcinoma (PLC) of the breast is a subtype of invasive lobular cancer which compromises approximately 1% of all epithelial breast malignancies and is characterized by higher nuclear pleomorphism and poorer prognosis than classic invasive lobular cancer (ILC). Since PLC is more aggressive than classical ILC, we examined the underlying molecular alterations in this subtype of breast cancer to understand the possible benefit from targeted therapies. Methods: In this study, we investigate the clinical characteristics and molecular alterations in 16 PLC from our institution. Additionally, we examined the clinical and genomic features in 31 PLC from the Cancer Genome Atlas (TCGA). Results: Overall, our analysis of PLC found that 28% had activating ERBB2 mutations, 21% had ERBB2 amplification, and 49% activating PIK3CA mutations. Among cases from our institution, we found 19% with activating ERBB2 mutations, 25% had ERBB2 amplification, and 38% with activating PIK3CA mutations. In data from TCGA, 32% had activating ERBB2 mutations, 19% had ERBB2 amplification, and 55% had activating PIK3CA mutations. While classic ILC in TCGA had similar percentages of PIK3CA alterations compared to PLC, activating ERBB2 alterations were exceedingly rare, with no activating ERBB2 mutations and only one case with ERBB2 amplification. Interestingly, in further examining TCGA data which included FGFR1 and PTEN, 94% of PLC had alterations in ERBB2, FGFR1, or the PI3K pathway. Conclusions: Our results show a high frequency of ERBB2 and PIK3CA alterations in PLC and suggest all PLC should be tested for potential therapeutic targeting.Keywords
All Related Versions
Funding Information
- National Institutes of Health (P30-CA072720)
This publication has 28 references indexed in Scilit:
- Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breastBreast Cancer Research and Treatment, 2015
- Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omicsBreast Cancer Research, 2015
- Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United StatesJAMA, 2015
- Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted TherapyJournal of Clinical Oncology, 2014
- Pleomorphic Lobular Carcinoma of the Breast: A Morphologically and Clinically Distinct Variant of Lobular CarcinomaArchives of Pathology & Laboratory Medicine, 2013
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerCancer Discovery, 2013
- Is pleomorphic lobular carcinoma really a distinct clinical entity?Journal of Surgical Oncology, 2008
- Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomasThe Journal of Pathology, 2008
- Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entityThe Journal of Pathology, 2005
- CD5+ T-Cell/Histiocyte-Rich Large B-Cell LymphomaLaboratory Investigation, 2002